Skip to main content
Premium Trial:

Request an Annual Quote

Schuh Surfaces as CEO of Arcturus, a Month after Resigning from Sequenom

NEW YORK, March 7 (GenomeWeb News) - Toni Schuh will serve as the new CEO of Arcturus, the company said today, almost exactly a month after Schuh stepped down as CEO of Sequenom.

 

Arcturus Bioscience, a privately held firm based in Mountain View, Calif., said that Schuh will also be elected to its board of directors.

 

Schuh succeeds former CEO and founder Thomas Baer, who resigned in late 2004 to serve as a consulting professor in the Applied Physics department at StanfordUniversity.

 

Baer continues to serve as a director of Arcturus. Richard Kniss, who has served as a member of the Arcturus Board since January 2002, will be appointed non-executive chairman, the company said.

 

Arcturus sells laser capture microdissection systems for the isolation of single cells, as well as reagents for genomic analysis of microscopic tissue samples.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.